Insight

Aug 31, 2024, 17:06

Amir Safavi: How to improve the safety of SABR for ultra central thoracic tumors?

Amir Safavi, Radiation Oncology Fellow at Memorial Sloan Kettering Cancer Centre ,shared a post on X:

“Risk mitigation strategies for ultracentral lung tumors in IJROBP – The Red Journal:

Moderate plan dmax (eg 110-120%).
Limit OAR hotspots (esp Esophagus).
Avoid overly generous PTV.
Nodes treated cooler (eg 35/5) Accurate target and OAR contouring (use contrast).“Beyond the HILUS Trial: How Can We Improve the Safety of SABR for Ultracentral Thoracic Tumors?Authors: Amir H. Safavi, David A. Palma and Meredith E. Giuliani

Source: Amir Safavi/X

Amir Safavi cancer David A. Palma IJROBP - The Red Journal LCSM Memorial Sloan Kettering Cancer Centre Meredith E. Giuliani OncoDaily Oncology SABR SBRT ultracentral lung

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage